Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
2007-09-10
2009-06-16
Wilson, James O (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
active
07547781
ABSTRACT:
The present invention relates to quinazoline containing zinc-binding moiety based derivatives that have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.
REFERENCES:
patent: 5457105 (1995-10-01), Barker
patent: 5616582 (1997-04-01), Barker et al.
patent: 5747498 (1998-05-01), Schnur et al.
patent: 5942514 (1999-08-01), Barker et al.
patent: 6087367 (2000-07-01), Breslow et al.
patent: 6184225 (2001-02-01), Thomas et al.
patent: 6414148 (2002-07-01), Thomas et al.
patent: 6777217 (2004-08-01), Schreiber et al.
patent: 6900221 (2005-05-01), Norris et al.
patent: 2004/0265228 (2004-12-01), Levitzki et al.
patent: 2006/0111375 (2006-05-01), Shimizo et al.
patent: 2008/0125448 (2008-05-01), Qian et al.
patent: 2008/0194578 (2008-08-01), Qian et al.
patent: 2008/0221132 (2008-09-01), Cai et al.
patent: 0268396 (2002-06-01), None
patent: 2004/105765 (2004-12-01), None
patent: 2005/097134 (2005-10-01), None
patent: 2005/097137 (2005-10-01), None
patent: 2006082428 (2006-08-01), None
patent: 2007131364 (2007-11-01), None
patent: 2008055068 (2008-08-01), None
Banker (Modern Pharmaceutics) Banker, G.S. et al, “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York, 1996, pp. 451 and 596.
Wolff, Manfred E. “Burger's Medicinal Chemistry, 5ed, Part I”, John Wiley & Sons, 1995, pp. 975-977.
Wood, Edgar R. et. al., “A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib): Relationships among Protein Conformation, Inhibitor Off-Rate, and Receptor Activity in Tumor Cells,” Cancer Research, 64: 6652-6659 (2004).
Matsuno, Kenji, et. al, “Potent and Selective Inhibitors of Platelet-Derived Growth Factor Receptor Phosphorylation. 3. Replacement of Quinazoline Moiety and Improvement of Metabolic Polymorphism of 4-[4-(N-Substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline Derivatives,” Journal of Medicinal Chemistry, 46: 4910-4925 (2003).
Ple', Patrick A., et. al., Discovery of a New Class of Anilinoquinazoline Inhibitors with High Affinity and Specificity for the Tyrosine Kinase Domain of c-Src, Journal of Medicinal Chemistry, 47: 871-887 (2004).
Patani, et al., “Bioisosterism—A Rational Approach in Drug Design,” Chem Rev. 96:3146-3176 (1996).
Office Action dated Nov. 14, 2008 in U.S. Appl. No. 11/852,474.
Cai Xiong
Gould Stephen
Qian Changgeng
Curis, Inc.
Elmore Carolyn S.
Elmore Patent Law Group P.C.
Harlan Edgar W.
McDowell Brian
LandOfFree
Quinazoline based EGFR inhibitors containing a zinc binding... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinazoline based EGFR inhibitors containing a zinc binding..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazoline based EGFR inhibitors containing a zinc binding... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4057199